Specifically, another study showed that the combination of the anti-CD73 antibody olecumab and the anti-PD-L1 antibody durvalumab significantly reduced tumor volume in an NSG mouse model carrying mEGFR NSCLC cells and showed that neither olecumab nor durvalumab alone significantly induced antitumor effects. This evidence concerns the gene CD274 and non-small cell lung carcinoma.